Cited by 1,294Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 207 of the 208 references it cites were found in a registry or an index.

Translational biology of osteosarcoma

Kansara, Maya, Teng, Michele W., Smyth, Mark J., Thomas, David M.·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.

Integrity signals

Registry

Crossref · 10.1038/nrc3838

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citation
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,072
WHO classification of tumours of soft tissue and bone
Fletcher, C. D. �. (2013) · Cited by 2,874
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478

Flagged first, then by citations

Show all 208 references

1 of the 208 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Lussier, D. M. et al. 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) 162 (Society for Immunotherapy of Cancer, 2013).

Sorted by citations

Items 201–300 of 1,000

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer
Liu, R., Hu, Y., Liu, T., & Wang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-09042-6 · Cited by 46
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017) · Tumor Biology · doi:10.1177/1010428317715643 · Cited by 45
18F-FDG PET/CT in the Management of Osteosarcoma
Oh, C., Bishop, M. W., Cho, S. Y., Im, H., & Shulkin, B. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265592 · Cited by 45
Molecular pathogenesis and therapeutic strategies of human osteosarcoma
Denduluri, S. K., Wang, Z., Yan, Z., Wang, J., Wei, Q., Mohammed, M. K., Haydon, R. C., Luu, H. H., & He, T. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150075 · Cited by 45
Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
Chen, X., Zhang, X., Cai, H., Yang, W., Lei, H., Xu, H., Wang, W., Zhu, Q., Kang, J., Tong, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.015 · Cited by 45
Innovative Biomaterials for the Treatment of Bone Cancer
Ambrosio, L., Raucci, M. G., Vadalà, G., Ambrosio, L., Papalia, R., & Denaro, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158214 · Cited by 45
Chemotherapy-Sensitized In Situ Vaccination for Malignant Osteosarcoma Enabled by Bioinspired Calcium Phosphonate Nanoagents
Wang, Y., Wu, Y., Li, L., Ma, C., Zhang, S., Lin, S., Zhang, L. W., Wang, Y., & Gao, M. (2023) · ACS Nano · doi:10.1021/acsnano.2c09685 · Cited by 44
Different Subtypes of Osteosarcoma: Histopathological Patterns and Clinical Behaviour
Rothzerg, E., Xu, J., & Wood, D. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4020011 · Cited by 44
Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy
Ballatori, S. E., & Hinds, P. W. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.1 · Cited by 45
Recent Advances in Mechanobiology of Osteosarcoma
Adamopoulos, C., Gargalionis, A. N., Piperi, C., & Papavassiliou, A. G. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25660 · Cited by 45
miR-328-3p mediates the anti-tumor effect in osteosarcoma via directly targeting MMP-16
Shi, J., An, G., Guan, Y., Wei, T., Peng, Z., Liang, M., & Wang, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0829-7 · Cited by 44
Targeted nanomedicines for the treatment of bone disease and regeneration
Ordikhani, F., Zandi, N., Mazaheri, M., Luther, G. A., Ghovvati, M., Akbarzadeh, A., & Annabi, N. (2020) · Medicinal Research Reviews · doi:10.1002/med.21759 · Cited by 45
Hemin particles-functionalized 3D printed scaffolds for combined photothermal and chemotherapy of osteosarcoma
Dang, W., Jin, Y., Yi, K., Ju, E., Zhuo, C., Wei, H., Wen, X., Wang, Y., Li, M., & Tao, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129919 · Cited by 44
Hydrogel Coatings of Implants for Pathological Bone Repair
Li, M., Fan, Y., Ran, M., Chen, H., Han, J., Zhai, J., Wang, Z., Ning, C., Shi, Z., & Yu, P. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401296 · Cited by 43
A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development
Wang, D., Wu, L., Cao, Y., Yang, L., Liu, W., Xiaoqiang, E., Ji, G., & Bi, Z. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.06.008 · Cited by 43
miR-21 predicts poor prognosis in patients with osteosarcoma
Ren, X., Shen, Y. S., Zheng, S., Liu, J., & Jiang, X. J. (2016) · British Journal of Biomedical Science · doi:10.1080/09674845.2016.1220710 · Cited by 43
Piezo-enhanced near infrared photocatalytic nanoheterojunction integrated injectable biopolymer hydrogel for anti-osteosarcoma and osteogenesis combination therapy
Xiao, C., Wang, R., Fu, R., Yu, P., Guo, J., Li, G., Wang, Z., Wang, H., Nie, J., Liu, W., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.01.003 · Cited by 42
3D and 4D printing of MXene-based composites: from fundamentals to emerging applications
Bigham, A., Zarepour, A., Khosravi, A., Iravani, S., & Zarrabi, A. (2024) · Materials Horizons · doi:10.1039/d4mh01056f · Cited by 42
The Roles of Circular RNAs in Osteosarcoma
Zhang, Y., Li, J., Wang, Y., Jing, J., & Li, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915559 · Cited by 42
Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells
Jiang, C., Ma, L., Lv, Z., Feng, F., Chen, Z., & Liu, Z. (2020) · Journal of Natural Medicines · doi:10.1007/s11418-020-01399-5 · Cited by 42
Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Xu, Y., Deng, C., Chen, H., Song, Y., Xu, H., Song, G., Wang, X., Luo, T., Chen, W., Ma, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1307 · Cited by 41
Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo
Xiong, S., Chachad, D., Zhang, Y., Gencel‐Augusto, J., Sirito, M., Pant, V., Yang, P., Sun, C., Chau, G. P., Qi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3376 · Cited by 42
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Ma, Z., Bolinger, A. A., Chen, H., & Zhou, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00948 · Cited by 42
Paris polyphyllaSuppresses Proliferation and Vasculogenic Mimicry of Human Osteosarcoma Cells and Inhibits Tumor GrowthIn Vivo
Yao, N., Ren, K., Wang, Y., Jin, Q., Lu, X., Lu, Y., Jiang, C., Zhang, D., Lü, J., Wang, C., et al. (2017) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x17500343 · Cited by 41
DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications
Sadoughi, F., Dana, P. M., Asemi, Z., & Yousefi, B. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103105 · Cited by 42
Recent advances on nanostructured biomaterials in osteosarcoma treatment
Feng, C., Jiang, Y., Wang, T., Tian, D., Shen, C., Wang, Y., & Qian, H. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215315 · Cited by 40
Integrated analysis of gene expression and genomic aberration data in osteosarcoma (OS)
Xiong, Y., Wu, S., Du, Q., Wang, A., & Wang, Z. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.48 · Cited by 40
Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death
Koyani, C. N., Kitz, K., Rossmann, C. R., Bernhart, E. M., Huber, E., Trummer, C., Windischhofer, W., Sattler, W., & Malle, E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.01.011 · Cited by 40
GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma
Luo, J., Xia, Y., Luo, J., Li, J., Zhang, C., Zhang, H., Ma, T., Yang, L., & Kong, L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.021 · Cited by 40
Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis
Wang, L., & Xue, G.-B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.054 · Cited by 40
Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach
Bao, Q., Gong, L., Wang, J., Wen, J., Shen, Y., & Zhang, W. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6642-z · Cited by 40
Wireless Electrochemotherapy by Selenium-Doped Piezoelectric Biomaterials to Enhance Cancer Cell Apoptosis
Li, C., Li, Y., Yao, T., Zhou, L., Xiao, C., Wang, Z., Zhai, J., Xing, J. Q., Chen, J., Tan, G., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c04666 · Cited by 40
Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma
Song, Y., Xu, Y., Zhu, X., Fu, J., Deng, C., Chen, H., Xu, H., Song, G., Lu, J., Tang, Q., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01198 · Cited by 41
Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway
Li, M., Yao, M., Wang, W., Wan, P., Chu, X., Zheng, Y., Yang, K., & Zhang, Y. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.019 · Cited by 40
circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR‐423‐5p to activate Wnt5a/Ror2 signaling
Wan, J., Liu, Y., Long, F., Tian, J., & Zhang, C. (2020) · Cancer Science · doi:10.1111/cas.14787 · Cited by 41
Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β-catenin nuclear translocation and LEF1 translation
Hu, S., Chang, J., Ruan, H., Zhi, W., Wang, X., Zhao, F., Ma, X., Sun, X., Liang, Q., Xu, H., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.51638 · Cited by 40
Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival
Casanova, J., Almeida, J. S., Reith, J. D., Sousa, L. M., Fonseca, R. L., Freitas-Tavares, P., Santos-Rosa, M., & Rodrigues‐Santos, P. (2021) · Cancers · doi:10.3390/cancers13236075 · Cited by 40
Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin
Zhang, Z., Tang, C. Y., Dong, Y., Zhang, J., Yuan, T., & Li, X. (2017) · Journal of Cancer · doi:10.7150/jca.22113 · Cited by 40
Data-Driven Mathematical Model of Osteosarcoma
Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39
Mapping the Single-Cell Differentiation Landscape of Osteosarcoma
Truong, D. D., Weistuch, C., Murgas, K. A., Admane, P. S., King, B. L., Lee, J. C., Lamhamedi-Cherradi, S.-E., Swaminathan, J., Daw, N. C., Gordon, N. B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0563 · Cited by 39
Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
Keremu, A., Aini, A., Maimaitirexiati, Y., Liang, Z., Aila, P., xierela, P., Tusun, A., Moming, H., & Yusufu, A. (2017) · Bioscience Reports · doi:10.1042/bsr20170080 · Cited by 39
Chalcone Derivatives 4′-Amino-1-Naphthyl-Chalcone (D14) and 4′-Amino-4-Methyl-1-Naphthyl-Chalcone (D15) Suppress Migration and Invasion of Osteosarcoma Cells Mediated by p53 Regulating EMT-Related Genes
Seba, V., SILVA, G. H. D. O., dos Santos, M. B., Baek, S. J., França, S. D. C., Fachin, A. L., Regasini, L. O., & Marins, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092838 · Cited by 39
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 41
Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma
Yang, P. C., Zhang, L., Wang, T., Liu, Q., Wang, J., Wang, Y., Tu, Z., & Lin, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259428 · Cited by 39
Retracted
Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models
Rodrigues, J., Sarmento, B. F. C. C., & Pereira, C. L. (2022) · In vitro models · doi:10.1007/s44164-022-00008-x · Cited by 41
Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
Xiang, D., Han, X.-L., Li, J., Zhang, J., Xiao, H., Li, T., Zhao, X., Xiong, H., Xu, M., & Bi, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100675 · Cited by 41
Anti-cancer activity oftrans-chalcone in osteosarcoma: Involvement of Sp1 and p53
SILVA, G. H. D. O., Marins, M., Fachin, A. L., Lee, S., & Baek, S. J. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22386 · Cited by 39
IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma
Li, Z., Geng, M., Ye, X., Ji, Y., Li, Y., Zhang, X., & Xu, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65255 · Cited by 40
Multimodal Imaging of Osteosarcoma: From First Diagnosis to Radiomics
Cè, M., Cellina, M. I., Ueanukul, T., Carrafiello, G., Manatrakul, R., Tangkittithaworn, P., Jaovisidha, S., Fuangfa, P., & RESNICK, D. (2025) · Cancers · doi:10.3390/cancers17040599 · Cited by 41
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity
Gatti, M., Solari, A., Pattarozzi, A., Campanella, C., Thellung, S., Maniscalco, L., Maria, R. D., Würth, R., Corsaro, A., Bajetto, A., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.002 · Cited by 39
Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma
Shi, K., Wang, S., Shen, B., Yu, F., Weng, D., & Lin, J. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1566-z · Cited by 38
Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo
Pan, P., Liu, Y., & Hsu, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060900 · Cited by 38
LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial‐mesenchymal transition via Wnt/β‐catenin signaling pathway
Ding, Q., Mo, F., Cai, X., Zhang, W., Wang, J., Yang, S., & Liu, X. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29607 · Cited by 38
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
Albarrán, V., Villamayor, M. L., Chamorro, J., Rosero, D. I., Pozas, J., Román, M. S., Calvo, J. C., de Aguado, P. P., Moreno, J. A., Guerrero, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213784 · Cited by 37
SIRPA enhances osteosarcoma metastasis by stabilizing SP1 and promoting SLC7A3-mediated arginine uptake
Wang, P., Song, Y., Li, H., Zhuang, J., Shen, X., Yang, W., Mi, R., Lu, Y., Yang, B., Ma, M., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216412 · Cited by 37
Selenite‐Releasing Bone Mineral Nanoparticles Retard Bone Tumor Growth and Improve Healthy Tissue Functions In Vivo
Wang, Y., Hao, H., Liu, H., Wang, Y., Li, Y., Yang, G., Ma, J., Mao, C., & Zhang, S. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500307 · Cited by 37
Alternol, a natural compound, exerts an anti‐tumour effect on osteosarcoma by modulating of STAT 3 and ROS / MAPK signalling pathways
Zuo, D., Zhou, Z., Wang, H., Zhang, T., Zang, J., Yin, F., Sun, W. Y., Chen, J., Duan, L., Xu, J., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12957 · Cited by 37
Diagnostic and prognostic implications of serum miR-101 in osteosarcoma
Yao, Z., Li, C., Liang, D., Jiang, X., Tang, J., Ye, L., Yuan, K., Ren, H., Yang, Z., Jin, D., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171103 · Cited by 37
Tomentosin Displays Anti-Carcinogenic Effect in Human Osteosarcoma MG-63 Cells via the Induction of Intracellular Reactive Oxygen Species
Lee, C. M., Lee, J., Nam, M. J., Choi, Y. S., & Park, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061508 · Cited by 37
RETRACTED: LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p
Pan, Z., Wu, C. T., Li, Y., Li, H., An, Y., Wang, G., Dai, J., & Wang, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109707 · Cited by 37
Retracted
Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma
Molina, E. R., Chim, L. K., Barrios, S., Ludwig, J. A., & Mikos, A. G. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2019.0302 · Cited by 38
Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells
Wang, Y., Wu, J., Chen, H., Yang, Y., Xiao, C., Yi, X., Shi, C., Zhong, K., He, H., Li, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3445 · Cited by 37
Ginsenoside Rh2 impedes proliferation and migration and induces apoptosis by regulating NF‐κB, MAPK, and PI3K/Akt/mTOR signaling pathways in osteosarcoma cells
Li, C., Gao, H., Feng, X., Bi, C., Zhang, J., & Yin, J. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22597 · Cited by 37
Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
Morales‐Molina, Á., Gambera, S., Leo, A., & Garcı́a-Castro, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001703 · Cited by 37
The FAP -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway
Ye, G., Huang, M., Li, Y., Ouyang, J., Chen, M., Wen, Q., Li, X., Zeng, H.-H., Long, P., Fan, Z., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.015 · Cited by 37
The role of m6A modification in pediatric cancer
Chen, Y., Miao, L., Lin, H., Zhuo, Z., & He, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188691 · Cited by 37
BMI1 promotes osteosarcoma proliferation and metastasis by repressing the transcription of SIK1
Wang, Q., Wu, Y., Lin, M., Wang, G., Liu, J., Xie, M., Zheng, B. J., Shen, C., & Shen, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02552-8 · Cited by 37
Antitumor effect of focal adhesion kinase inhibitor PF 562271 against human osteosarcoma in vitro and in vivo
Hu, C., Xu, C. Y., Wen, J., Gong, L., Liu, Z., Wang, J., Liang, J., Hu, F., Zhou, Q., Li, W., et al. (2017) · Cancer Science · doi:10.1111/cas.13256 · Cited by 37
Clinical significance of serum soluble B7-H3 in patients with osteosarcoma
Wang, L., Kang, F., Zhang, G., Wang, J., Xie, M., & Zhang, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0614-z · Cited by 36
RETRACTED ARTICLE: Down-regulation of long non-coding RNA ITGB2-AS1 inhibits osteosarcoma proliferation and metastasis by repressing Wnt/β-catenin signalling and predicts favourable prognosis
Dai, J., Xu, L., Han, G.-D., Jiang, H., Sun, H., Zhu, G., & Tang, X. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1511576 · Cited by 36
Retracted
PLK1 contributes to autophagy by regulating MYC stabilization in osteosarcoma cells
Mo, H., He, J., Yuan, Z., Wu, Z., Liu, B., Lin, X., & Guan, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s210575 · Cited by 36
Retracted
Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy
Tong, F., Ye, Y., Chen, B., Gao, J., Liu, L., Ou, J., van Hest, J. C. M., Liu, S., Peng, F., & Tu, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c08992 · Cited by 36
Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
Lallier, M., Marchandet, L., Moukengué, B., Charrier, C., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2021) · Cells · doi:10.3390/cells10040754 · Cited by 30
Osteosarcoma‐Derived Exosomes as Potential PET Imaging Nanocarriers for Lung Metastasis
Almeida, S. F. F., Fonseca, A. I., Sereno, J., Ferreira, H. R. S., Pais, M., Martins‐Marques, T., Ribeiro‐Rodrigues, T., Oliveira, R. C., Miranda, C. O., de Almeida, L. P., et al. (2022) · Small · doi:10.1002/smll.202203999 · Cited by 36
Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival
Lu, Y. W., GUAN, G.-F., Chen, J., Hu, B., Sun, C., Ma, Q., Wen, Y., Qiu, X., & Zhou, Y. (2015) · Oncology Letters · doi:10.3892/ol.2015.3535 · Cited by 36
NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance
Shi, S., Ou, X., Liu, C., Li, R., Zheng, Q., & Hu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1518664 · Cited by 37
miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis
Song, Y.-C., Li, D.-D., Guan, Y., Wang, Y.-L., & Zheng, J. (2017) · Cellular and Molecular Biology · doi:10.14715/cmb/2017.63.9.14 · Cited by 35
A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma
Huang, C., Wang, Q., Ma, S., Sun, Y., Vadamootoo, A. S., & Jin, C. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01433-x · Cited by 35
Ezrin/NF-κB Pathway Regulates EGF-induced Epithelial-Mesenchymal Transition (EMT), Metastasis, and Progression of Osteosarcoma
Liu, P., Yang, P. H., Zhang, Z., Liu, M., & Hu, S. (2018) · Medical Science Monitor · doi:10.12659/msm.906945 · Cited by 35
Identification of potential crucial genes and key pathways in osteosarcoma
Liu, J., Wu, S., Xie, X., Wang, Z., & Lei, Q. (2020) · Hereditas · doi:10.1186/s41065-020-00142-0 · Cited by 35
Circ_0000285 regulates proliferation, migration, invasion and apoptosis of osteosarcoma by miR-409-3p/IGFBP3 axis
Long, Z., Gong, F., Li, Y., Fan, Z., & Li, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01557-5 · Cited by 35
Immune classification of osteosarcoma
Le, T., Department of Mathematics and Statistics, U. O. M. A., Su, S., & Shahriyari, L. (2021) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2021098 · Cited by 35
Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment
Zhang, Y., Yuan, T., Li, Z., Luo, C., Wu, Y., Zhang, J., Zhang, X., & Fan, W. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00081 · Cited by 35
Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis
Zeng, C., Zhong, L., Liu, W., Zhang, Y., Yu, X., Wang, X., Zhang, R., Kang, T., & Liao, D. (2022) · Advanced Science · doi:10.1002/advs.202205483 · Cited by 37
Nanosecond pulsed electric field inhibits proliferation and induces apoptosis in human osteosarcoma
Miao, X., Yin, S., Shao, Z., Zhang, Y., & Chen, X. (2015) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-015-0247-z · Cited by 35
RETRACTED: Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a
Li, C., Zhang, S., Qiu, T., Wang, Y., Ricketts, D., & Qi, C. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1538612 · Cited by 34
Retracted
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
Fernandes, I., Melo-Alvim, C., Lopes-Brás, R., Esperança‐Martins, M., & Costa, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020813 · Cited by 34
Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways
Huang, Z. D., Wang, S., Wei, H., Chen, H., Shen, R., Lin, R., Wang, X., Lan, W., Lin, R., & Jianhua, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16805 · Cited by 34
Destabilization of macrophage migration inhibitory factor by 4‐IPP reduces NF‐κB/P‐TEFb complex‐mediated c‐Myb transcription to suppress osteosarcoma tumourigenesis
Zheng, L., Feng, Z., Tao, S., Gao, J., Lin, Y., Wei, X., Zheng, B., Huang, B. H., Zheng, Z., Zhang, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.652 · Cited by 34
LDHB may be a significant predictor of poor prognosis in osteosarcoma.
Li, C., Chen, Y., Bai, P., Wang, J., Liu, Z., Wang, T., & Cai, Q. (2016) · PubMed Central · Cited by 34
Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells
Mamo, T., Mladek, A. C., Shogren, K. L., Gustafson, C. T., Gupta, S. K., Riester, S. M., Maran, A., Galindo, M. A., van Wijnen, A. J., Sarkaria, J. N., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.033 · Cited by 34
A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines.
Haghiralsadat, F., Amoabediny, G., Sheikhha, M. H., Forouzanfar, T., Helder, M. N., & Zandieh‐Doulabi, B. (2017) · Europe PMC (PubMed Central) · doi:10.22074/cellj.2017.4502 · Cited by 34
Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis
Sheng, G., Gao, Y., Wu, H. K., Liu, Y., & Yang, Y. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03623-w · Cited by 33
Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
Patkar, S., Mannheimer, J., Harmon, S. A., Ramirez, C. J., Mazcko, C. N., Choyke, P. L., Brown, G. T., Türkbey, B., LeBlanc, A. K., & Beck, J. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1854 · Cited by 35
Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFα-induced low-grade inflammation
Perego, S., Sansoni, V., Banfi, G., & Lombardi, G. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/0394632017752240 · Cited by 33
Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis
Zou, Y., Guo, S., Wen, L., Lv, D., Tu, J., Liao, Y., Chen, W., Chen, Z., Li, H., Chen, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101728 · Cited by 32
Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3 Kinase/Protein Kinase B (PI3K/Akt) Signal Pathway Activation.
Chen, Z.-Z. (2016) · Europe PMC (PubMed Central) · Cited by 32
Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metallopeptidase-9 expression
Huynh, D. L., Kwon, T., Zhang, J., Sharma, N., Gera, M., Ghosh, M., Kim, N., Cho, S. K., Lee, D. S., Park, Y. H., et al. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1788-y · Cited by 32
Tissue engineered models of healthy and malignant human bone marrow
Chramiec, A. G., & Vunjak‐Novakovic, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.003 · Cited by 33
Molecular findings in maxillofacial bone tumours and its diagnostic value
Cleven, A. H. G., Schreuder, W. H., Groen, E., Kroon, H. M. J. A., & Baumhoer, D. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02726-2 · Cited by 32

Authors: Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M.
Affiliations: The University of Melbourne (AU)
The University of Queensland (AU)
Garvan Institute of Medical Research (AU)
Corresponding author: Thomas, David M.
ORCID: Kansara, Maya
Teng, Michele W.
Smyth, Mark J.
Thomas, David M.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-10-16
Volume: 14
Issue: 11
Pages: 722-735
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3838
OpenAlex: W1980088710
Cited by: 1,294
References: 208
Citations by year: 2026: 66 · 2025: 130 · 2024: 134 · 2023: 155 · 2022: 161 · 2021: 173 · 2020: 152 · 2019: 86 · 2018: 66 · 2017: 74 · 2016: 65 · 2015: 29 · 2014: 2
FWCI: 9.69
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: osteosarcoma, bone biology, bone homeostasis, germline predisposition, cancer genomics, chromothripsis, kataegis, genomic instability, targeted therapy, mifamurtide, immune checkpoint inhibitors, adjuvant therapy, metastatic osteosarcoma, translational research
MeSH terms: Animals, Antineoplastic Agents, Bone Development, Humans, Osteosarcoma, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Translational biology of osteosarcoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks